Platelet rich plasma (PRP) and Micrografts containing human follicle mesenchymal stem cells (HF-MSCs) were tried as a potential treatment for androgenetic alopecia (AGA). However, little to no work has yet to be seen wherein the bio-molecular pathway of HF-MSCs or PRP treatments were analyzed. The aims of this work are to report the clinical effectiveness of HF-MSCs and platelet-rich plasma evaluating and reviewing the most updated information related to the bio-molecular pathway. Twenty-one patients were treated with HF-MSCs injections and 57 patients were treated with A-PRP. The Wnt pathway and Platelet derived-growth factors effects were analyzed. 23 weeks after the last treatment with mean hair thickness increments (29 ± 5.0%) over baseline values for the targeted area. 12 weeks after the last injection with A-PRP mean hair count and hair density (31 ± 2%) increases significantly over baseline values. The increment of Wnt signaling in Dermal Papilla Cells evidently is one of the principal factors that enhances hair growth. Signaling from mesenchymal stem cells and platelet derived growth factors positively influences hair growth through cellular proliferation to prolong the anagen phase (FGF-7), inducing cell growth (ERK activation), stimulating hair follicle development (β-catenin), and suppressing apoptotic cues (Bcl-2 release and Akt activation).

Gentile, P., Scioli, M.g., Bielli, A., De Angelis, B., Sio, C.d., De Fazio, D., et al. (2019). Platelet-rich plasma and micrografts enriched with autologous human follicle mesenchymal stem cells improve hair re-growth in androgenetic alopecia. Biomolecular pathway analysis and clinical evaluation. BIOMEDICINES, 7(2), 27 [10.3390/biomedicines7020027].

Platelet-rich plasma and micrografts enriched with autologous human follicle mesenchymal stem cells improve hair re-growth in androgenetic alopecia. Biomolecular pathway analysis and clinical evaluation

Gentile P.
;
Bielli A.;De Angelis B.;Orlandi A.;Cervelli V.;
2019-01-01

Abstract

Platelet rich plasma (PRP) and Micrografts containing human follicle mesenchymal stem cells (HF-MSCs) were tried as a potential treatment for androgenetic alopecia (AGA). However, little to no work has yet to be seen wherein the bio-molecular pathway of HF-MSCs or PRP treatments were analyzed. The aims of this work are to report the clinical effectiveness of HF-MSCs and platelet-rich plasma evaluating and reviewing the most updated information related to the bio-molecular pathway. Twenty-one patients were treated with HF-MSCs injections and 57 patients were treated with A-PRP. The Wnt pathway and Platelet derived-growth factors effects were analyzed. 23 weeks after the last treatment with mean hair thickness increments (29 ± 5.0%) over baseline values for the targeted area. 12 weeks after the last injection with A-PRP mean hair count and hair density (31 ± 2%) increases significantly over baseline values. The increment of Wnt signaling in Dermal Papilla Cells evidently is one of the principal factors that enhances hair growth. Signaling from mesenchymal stem cells and platelet derived growth factors positively influences hair growth through cellular proliferation to prolong the anagen phase (FGF-7), inducing cell growth (ERK activation), stimulating hair follicle development (β-catenin), and suppressing apoptotic cues (Bcl-2 release and Akt activation).
2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/19 - CHIRURGIA PLASTICA
English
Con Impact Factor ISI
HF-MSCs; PRP; PRP hair; hair loss; hair-regrowth; human follicle mesenchymal stem cells; micrografts; platelet rich plasma; stem cells hair
Gentile, P., Scioli, M.g., Bielli, A., De Angelis, B., Sio, C.d., De Fazio, D., et al. (2019). Platelet-rich plasma and micrografts enriched with autologous human follicle mesenchymal stem cells improve hair re-growth in androgenetic alopecia. Biomolecular pathway analysis and clinical evaluation. BIOMEDICINES, 7(2), 27 [10.3390/biomedicines7020027].
Gentile, P; Scioli, Mg; Bielli, A; De Angelis, B; Sio, Cd; De Fazio, D; Ceccarelli, G; Trivisonno, A; Orlandi, A; Cervelli, V; Garcovich, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
biomedicines-april 2019.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 804.1 kB
Formato Adobe PDF
804.1 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/216639
Citazioni
  • ???jsp.display-item.citation.pmc??? 49
  • Scopus 98
  • ???jsp.display-item.citation.isi??? 93
social impact